Related Experiment Videos

Antiphospholipid antibodies in migraine

C Iñiguez1, C Pascual, A Pardo

  • 1Servicio de Neurologia, Hospital Ramón y Cajal, Madrid, Spain.

Headache
|November 1, 1991
PubMed

Insights

Antiphospholipid antibodies (APA) were found in 14% of migraine patients but not in controls. These antibodies did not appear to influence migraine clinical features or long-term outcomes.

Area of Science:

  • Neurology
  • Immunology
  • Rheumatology

Background:

  • Migraine is a common neurological disorder.
  • Antiphospholipid antibodies (APA) are associated with autoimmune conditions and thrombosis.
  • The role of APA in migraine pathogenesis is not well understood.

Purpose of the Study:

  • To investigate the prevalence of serum APA in migraine patients.
  • To compare APA levels between migraine patients and healthy controls.
  • To evaluate the clinical significance of APA in migraine.

Main Methods:

  • Serum samples were collected from 35 migraine patients and 75 controls.
  • Antiphospholipid antibodies (APA) were measured using serological assays.
  • Clinical features and follow-up data were collected for all participants.

Main Results:

  • APA were detected in 5 out of 35 migraine patients (p = 0.003).
  • No APA were found in the 75 controls.
  • Clinical characteristics and one-to-two-year follow-up showed no significant differences or complications related to APA presence.

Conclusions:

  • APA are present in a subset of migraine patients.
  • APA do not appear to be a significant factor in the pathogenesis or long-term course of migraine in otherwise healthy individuals.
  • Further research may be needed to clarify the specific role, if any, of APA in certain migraine subtypes.

Related Concept Videos